In response to an enquiry regarding a possible discrepancy in our original Table 2 data, we -the authors of the paper -recalculated the material. We were able to confirm that our original calculation of the raw data -which had excluded certain missing values -was appropriate, but in recalculating we found minor errors in the Table 2 values. We have corrected these. A revised Table 2 , with new values indicated in boldface, is below.
The online version of the original article can be found at http://dx.doi.org/ 10.1007/s00251-013-0679-8.
In response to an enquiry regarding a possible discrepancy in our original Table 2 data, we -the authors of the paper -recalculated the material. We were able to confirm that our original calculation of the raw data -which had excluded certain missing values -was appropriate, but in recalculating we found minor errors in the Table 2 values. We have corrected these. A revised Table 2 , with new values indicated in boldface, is below. The corrections do not affect any statistical differences among the genotypes or any of the article's results and conclusions.
We have also corrected an unintentional inaccuracy in the sentence 'NK cells and PBMCs from V/V patients also showed higher infliximab-binding affinity and infliximabmediated ADCC activity, respectively.'
The sentence should read 'NK cells and PBMCs from V/V healthy donors also showed higher infliximabbinding affinity and infliximab-mediated ADDCC activity, respectively. ' We, the authors, sincerely regret any confusion the errors might have caused, and are grateful that they were brought to our attention.
